@article {RN1299,
	title = {Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions},
	journal = {Lancet Gastroenterol Hepatol},
	year = {2024},
	type = {Journal Article},
	issn = {2468-1253 (Electronic)},
	doi = {10.1016/S2468-1253(23)00335-7},
	url = {http://www.ncbi.nlm.nih.gov/pubmed/38367631},
	author = {Marshall, A. D. and Willing, A. R. and Kairouz, A. and Cunningham, E. B. and Wheeler, A. and O{\textquoteright}Brien, N. and Perera, V. and Ward, J. W. and Hiebert, L. and Degenhardt, L. and Hajarizadeh, B. and Colledge, S. and Hickman, M. and Jawad, D. and Lazarus, J. V. and Matthews, G. V. and Scheibe, A. and Vickerman, P. and Dore, G. J. and Grebely, J. and Global, H. C. V. and Group, H. I. V. Treatment Restrictions}
}
